Q3 2017 Earnings Forecast for Sophiris Bio, Inc. Issued By Zacks Investment Research (SPHS)
Sophiris Bio, Inc. (NASDAQ:SPHS) – Equities research analysts at Zacks Investment Research lowered their Q3 2017 EPS estimates for Sophiris Bio in a report issued on Tuesday. Zacks Investment Research analyst D. Bautz now forecasts that the biopharmaceutical company will post earnings of ($0.09) per share for the quarter, down from their previous forecast of ($0.08). Zacks Investment Research also issued estimates for Sophiris Bio’s Q4 2017 earnings at ($0.09) EPS, FY2017 earnings at ($0.24) EPS, FY2018 earnings at ($0.35) EPS and FY2019 earnings at ($0.39) EPS.
Sophiris Bio (NASDAQ:SPHS) last issued its earnings results on Monday, May 15th. The biopharmaceutical company reported ($0.09) EPS for the quarter, hitting the consensus estimate of ($0.09).
COPYRIGHT VIOLATION NOTICE: “Q3 2017 Earnings Forecast for Sophiris Bio, Inc. Issued By Zacks Investment Research (SPHS)” was first published by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/08/18/q3-2017-earnings-forecast-for-sophiris-bio-inc-issued-by-zacks-investment-research-sphs.html.
Other equities analysts have also issued research reports about the company. HC Wainwright set a $6.00 price target on Sophiris Bio and gave the company a “buy” rating in a research report on Saturday, June 10th. Maxim Group set a $6.00 price target on Sophiris Bio and gave the company a “buy” rating in a research report on Monday. ValuEngine lowered Sophiris Bio from a “hold” rating to a “sell” rating in a research report on Tuesday, June 13th. Finally, Rodman & Renshaw reiterated a “buy” rating and issued a $6.00 price target on shares of Sophiris Bio in a research report on Thursday, June 1st. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $6.60.
Shares of Sophiris Bio (NASDAQ SPHS) opened at 1.8599 on Friday. The firm’s 50 day moving average is $2.03 and its 200 day moving average is $2.42. The stock’s market capitalization is $56.00 million. Sophiris Bio has a 12 month low of $1.80 and a 12 month high of $6.13.
An institutional investor recently bought a new position in Sophiris Bio stock. Mesirow Financial Investment Management Inc. acquired a new position in shares of Sophiris Bio, Inc. (NASDAQ:SPHS) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 54,510 shares of the biopharmaceutical company’s stock, valued at approximately $120,000. Mesirow Financial Investment Management Inc. owned 0.18% of Sophiris Bio at the end of the most recent reporting period. 5.50% of the stock is currently owned by institutional investors and hedge funds.
Sophiris Bio Company Profile
Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).
Receive News & Ratings for Sophiris Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.